Compile Data Set for Download or QSAR
Report error Found 38 Enz. Inhib. hit(s) with all data for entry = 182
TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204784(US9540396, 38 | 6-(2-fluoro-4-iodophenylamino)-7-(...)
Affinity DataIC50: 100nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204732(US9540396, 5 | (s)-6-(2-fluoro-4-iodophenylamino)-...)
Affinity DataIC50: 100nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204731(US9540396, 4 | (s)-6-(2-fluoro-4-iodophenylamino)-...)
Affinity DataIC50: 100nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204738(US9540396, 10 | (s)-6-(2-fluoro-4-iodophenylamino)...)
Affinity DataIC50: 100nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204616(US9540396, 1 | 6-(2-fluoro-4-iodophenylamino)-n-(2...)
Affinity DataIC50: 100nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204737(US9540396, 9 | (r) n-(2,3-dihydroxypropoxy)-6-(2-f...)
Affinity DataIC50: 100nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204747(US9540396, 17 | 6-(2-chloro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 100nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204736(US9540396, 8 | 6-(2-fluoro-4-iodophenylamino)-n-(1...)
Affinity DataIC50: 100nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204735(US9540396, 7 | n-(cyclopropylmethoxy)-6-(2-fluoro-...)
Affinity DataIC50: 100nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204770(US9540396, 30 | 6-(2-fluoro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 500nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204744(US9540396, 14 | n-ethoxy-6-(2-fluoro-4-iodophenyla...)
Affinity DataIC50: 500nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204742(US9540396, 13 | 6-(2-fluoro-4-iodophenylamino)-n-m...)
Affinity DataIC50: 500nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204768(US9540396, 28 | 2-((dimethylamino)methyl)-6-(2-flu...)
Affinity DataIC50: 500nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204765(US9540396, 27 | (r) n-(2,3-dihydroxypropoxy)-6-(2-...)
Affinity DataIC50: 500nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204729(US9540396, 2 | 6-(2-fluoro-4-iodophenylamino)-n-(2...)
Affinity DataIC50: 500nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204772(US9540396, 32 | 6-(2-fluoro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 500nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204771(US9540396, 31 | 2-amino-6-(2-fluoro-4-iodophenylam...)
Affinity DataIC50: 500nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204734(US9540396, 6 | 6-(2-fluoro-4-iodophenylamino)-n-(2...)
Affinity DataIC50: 500nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204782(US9540396, 36 | 6-(2-chloro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 500nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204756(US9540396, 20 | 6-(2-fluoro-4-(methylthio)phenylam...)
Affinity DataIC50: 500nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204781(US9540396, 35 | 6-(2-chloro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 500nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204755(US9540396, 19 | 6-(2-fluoro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 500nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204764(US9540396, 26 | 6-(2-fluoro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 500nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204762(US9540396, 24 | 6-(2-fluoro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 500nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204758(US9540396, 22 | 6-(2-fluoro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 1.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204783(US9540396, 37 | 6-(2-fluoro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 1.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204757(US9540396, 21 | 6-(2-chloro-4-(methylthio)phenylam...)
Affinity DataIC50: 1.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204741(US9540396, 12 | 6-(4-bromo-2-chlorophenylamino)-n-...)
Affinity DataIC50: 1.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204773(US9540396, 33 | 6-(2-fluoro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 1.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204746(US9540396, 16 | n-(2,3-dihydroxypropyl)-6-(2-fluor...)
Affinity DataIC50: 1.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204745(US9540396, 15 | 6-(2-fluoro-4-iodophenylamino)-5-m...)
Affinity DataIC50: 1.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204769(US9540396, 29 | 6-(2-fluoro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 1.00E+4nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204730(US9540396, 3 | 6-(4-bromo-2-fluorophenylamino)-n-(...)
Affinity DataIC50: 1.00E+4nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204740(US9540396, 11 | 6-(2,4-dichlorophenylamino)-n-(2-h...)
Affinity DataIC50: 1.00E+4nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204777(US9540396, 34 | 6-(2-fluoro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 1.00E+4nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204754(US9540396, 18 | 6-(2-fluoro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 1.00E+4nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204763(US9540396, 25 | 6-(2-fluoro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 1.00E+4nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent

TargetDual specificity mitogen-activated protein kinase kinase 1(Human)
Centaurus Biopharma

US Patent
LigandPNGBDBM204759(US9540396, 23 | 6-(2-fluoro-4-iodophenylamino)-n-(...)
Affinity DataIC50: 1.00E+4nMpH: 7.4 T: 2°CAssay Description:Compounds were diluted from DMSO stocks into 1× buffer (20 mM MOPS, PH 7.4, 5 mM MgCl2, 0.5 mM MnCl2, 100 uM Sodium Orthovanadate, 0.01% Triton X-100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2018
Entry Details
US Patent